𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Systematic characterisation of GABRP expression in sporadic breast cancer and normal breast tissue

✍ Scribed by Menelaos Zafrakas; Marina Chorovicer; Irima Klaman; Glen Kristiansen; Peter-Johannes Wild; Uwe Heindrichs; Ruth Knüchel; Edgar Dahl

Publisher
John Wiley and Sons
Year
2005
Tongue
French
Weight
466 KB
Volume
118
Category
Article
ISSN
0020-7136

No coin nor oath required. For personal study only.

✦ Synopsis

The GABRP gene has been previously identified by in silico analysis of four million ESTs as a candidate gene differentially expressed in breast cancer. GABRP is located on chromosome 5q34 and it encodes the pi-subunit of the gamma-aminobutyric acid (GABA) receptor, a transmembrane protein expressed in the brain and several nonneuronal tissues. Using cDNA dot blot hybridisation (cancer profiling array), quantitative RT-PCR and non-radioisotopic in situ hybridisation (ISH), we have analysed GABRP expression in breast cancer and normal breast tissues as well as in nontumorigenic and tumorigenic breast cell lines. Analysis of the cancer profiling array revealed a more than 2-fold downregulation of GABRP (p < 0.001) in 76% of primary breast carcinomas (n = 50) compared to corresponding normal tissues. Quantitative RT-PCR in a panel of 23 normal human tissues showed that the GABRP expression level was most abundant in the normal breast tissues compared to other human tissues. GABRP downregulation in breast cancer was confirmed by quantitative RT-PCR in cryopreserved breast tumour and normal breast tissue specimens (n = 22), in archival formalin-fixed, paraffin-embedded tissue specimens (n = 32), as well as in breast cancer cell lines (n = 8). Furthermore, a significant downregulation of GABRP was noted in large (pT3-pT4) (p = 0.044) primary breast tumours. Non-radioisotopic ISH showed strong GABRP expression in normal epithelial and benign papilloma breast cells, but no signal could be detected in invasive ductal carcinoma. Altogether, these data suggest that GABRP is progressively down-regulated with tumour-progression, and that it may be useful as a prognostic marker in breast cancer.

📜 SIMILAR VOLUMES

Midkine and pleiotrophin expression in n
Midkine and pleiotrophin expression in normal and malignant breast tissue
✍ Robert I. Garver Jr.; Diane M. Radford; Helen Donis-Keller; Mark R. Wick; Peter 📂 Article 📅 1994 🏛 John Wiley and Sons 🌐 English ⚖ 805 KB

Background. Some growth factors may promote tumor growth by affecting tumor angiogenesis. The angiogenic growth factor, pleiotrophin, was demonstrated previously in human breast carcinoma tissues; however, the pattern of pleiotrophin expression in normal breast tissues has not been established. Met

Lipophilin B: A gene preferentially expr
Lipophilin B: A gene preferentially expressed in breast tissue and upregulated in breast cancer
✍ Jane Culleton; Neil O'Brien; Bríd M. Ryan; Arnold D.K. Hill; Enda McDermott; Nia 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 French ⚖ 135 KB

## Abstract Lipophilin B (LPB), which is also known as BU101, is a secretoglobin which exists __in vivo__ as a complex with the mammary‐specific protein, mammaglobin A (MGA). The aim of our study was to investigate the expression of LPB in a panel of breast and nonbreast tissues and compare its exp

Expression of glycodelin in human breast
Expression of glycodelin in human breast and breast cancer
✍ Meerit Kämäräinen; Mervi Halttunen; Riitta Koistinen; Kristina von Boguslawsky; 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 French ⚖ 309 KB 👁 2 views

Glycodelin is a 28 kDa glycoprotein with structural homology to ␤-lactoglobulins, particularly expressed in steroidresponsive tissues of the female reproductive tract. We previously found that transfection of glycodelin cDNA into MCF-7 breast cancer cells induces differentiation into organized acina

Oestrogen receptor expression in the nor
Oestrogen receptor expression in the normal and pre-cancerous breast
✍ Shoker, Balvinder S.; Jarvis, Christine; Sibson, D. Ross; Walker, Carol; Sloane, 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 413 KB 👁 2 views

As oestrogen is associated with most of the epidemiological risk factors for breast cancer, the number and distribution of oestrogen receptor positive (ER+) cells could have a bearing on the development of the disease. ER+ cells were thus studied in the normal breast and in the spectrum of in situ p

Preferential allelic expression can lead
Preferential allelic expression can lead to reduced expression of BRCA1 in sporadic breast cancers
✍ Hilmi Özçelik; Minh D. To; Jean Couture; Shelley B. Bull; Irene L. Andrulis 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 French ⚖ 101 KB 👁 2 views

BRCA1 is considered to be a tumor-suppressor gene, yet mutations in this gene are uncommon in sporadic breast tumors. We investigated whether mechanisms other than DNA mutations that affect the coding region might be involved in breast carcinogenesis. Since loss of expression of the BRCA1 gene would

Fas ligand is expressed in normal breast
Fas ligand is expressed in normal breast epithelial cells and is frequently up-regulated in breast cancer
✍ M�llauer, Leonhard; Mosberger, Isabella; Grusch, Michael; Rudas, Margarete; Chot 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 409 KB 👁 1 views

Fas (CD95/Apo-1) is a cell membrane receptor that upon binding by its ligand (FasL), triggers a signal resulting in apoptotic cell death. Fas is produced by breast epithelial cells, but its contribution to breast tissue homeostasis is unknown. This study investigated whether FasL is synthesized in t